We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The European Federation of Pharmaceutical Industries and Associations (EFPIA), European Biopharmaceutical Enterprises (EBE) and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) have issued joint guidance...
The US Food and Drug Administration (FDA) has accepted Roche’s supplemental Biologics Licence Application (sBLA) and granted priority review for Tecentriq (atezolizumab) to treat people with locally advanced or metastatic urothelial carcinoma (mUC).